N-乙基-3-三氟甲基苄胺 | 14355-04-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯胺系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-3-三氟甲基苄胺
• 英文名称: N-(3-(trifluoromethyl)benzyl)ethanamine
• 英文别名: Benzenemethanamine, N-ethyl-3-(trifluoromethyl)-；N-[[3-(trifluoromethyl)phenyl]methyl]ethanamine
• CAS: 14355-04-5
• 化学式: C₁₀H₁₂F₃N
• mdl: MFCD09935363
• 分子量: 203.207
• InChiKey: MGSDOCJVFWZVGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2921499090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  9-咔唑乙酸 、 N-乙基-3-三氟甲基苄胺 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以76%的产率得到2-(9H-carbazol-9-yl)-N-ethyl-N-(3-(trifluoromethyl)benzyl)acetamide
  参考文献：
  名称：

  First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold

  摘要：

  Development of neuroinflammation agents targeting the translocator protein (TSPO) has been hindered by a common single nucleotide polymorphism (A147T) at which TSPO ligands commonly lose affinity. To this end, carbazole acetamide scaffolds were synthesized and structure activity relationships elaborated to explore the requirements for high-affinity binding to both TSPO wild type (WT) and the polymorphic TSPO A147T. This study reports high binding affinity and nondiscriminating TSPO ligands.

  DOI：

  10.1021/acs.jmedchem.9b00980
• 作为产物：
  描述：

  3-三氟甲基苯甲醛 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 N-乙基-3-三氟甲基苄胺
  参考文献：
  名称：

  Benzylamines: synthesis and evaluation of antimycobacterial properties

  摘要：

  The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (19, MIC 10.2 micrograms/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 micrograms/mL), and N-butyl-3,5-difluorobenzylamine (103, MIC 6.4 micrograms/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combinations of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

  DOI：

  10.1021/jm00375a005

文献信息

• [EN] TEAD INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE TEAD ET LEURS UTILISATIONS
  申请人：IKENA ONCOLOGY INC

  公开号：WO2020243423A1

  公开（公告）日：2020-12-03

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME
  申请人：ZOGENIX INTERNATIONAL LIMITED

  公开号：US20170174613A1

  公开（公告）日：2017-06-22

  Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2-(3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

  提供了制备芬氟拉明活性药物成分的方法。该方法的步骤包括（a）水解2-(3-(三氟甲基)苯基)乙腈组合物，以产生2-(3-(三氟甲基)苯基)乙酸组合物；（b）将2-(3-(三氟甲基)苯基)乙酸组合物与乙酸酐和催化剂反应，以产生1-(3-(三氟甲基)苯基)丙酮组合物；以及（c）使用硼氢化还原剂将1-(3-(三氟甲基)苯基)丙酮组合物与乙胺还原胺化，以产生芬氟拉明组合物。还提供了根据该方法制备的组合物和药用成分，包括芬氟拉明的药用可接受盐，并且在总三氟甲基异构体中的重量不到0.2%。
• [EN] FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME<br/>[FR] COMPOSITIONS DE FENFLURAMINE ET PROCÉDÉS DE PRÉPARATION DE CELLES-CI
  申请人：ZOGENIX INT LTD

  公开号：WO2017112702A1

  公开（公告）日：2017-06-29

  Methods of preparing a fenfluramine active pharmaceutical ingredient are provided. Aspects of the method include (a) hydrolyzing a 2-(3-(trifluoromethyl)phenyl)acetonitrile composition to produce a 2-(3-(trifluoromethyl)phenyl)acetic acid composition; (b) reacting the 2- (3-(trifluoromethyl)phenyl)acetic acid composition with acetic anhydride and a catalyst to produce a 1-(3-(trifluoromethyl)phenyl)propan-2-one composition; and (c) reductively aminating the 1-(3-(trifluoromethyl)phenyl)propan-2-one composition with ethylamine using a borohydride reducing agent to produce a fenfluramine composition. Also provided are compositions and pharmaceutical ingredients prepared according to the subject methods including a pharmaceutically acceptable salt of fenfluramine and having less than 0.2% by weight in total of trifluoromethyl regioisomers.

  提供了制备芬氟拉明活性药物成分的方法。该方法的步骤包括：（a）水解2-（3-三氟甲基）苯乙腈组成物，以产生2-（3-三氟甲基）苯乙酸组成物；（b）将2-（3-三氟甲基）苯乙酸组成物与乙酸酐和催化剂反应，以产生1-（3-三氟甲基）丙酮组成物；以及（c）使用硼氢化还原剂将1-（3-三氟甲基）丙酮组成物与乙胺还原胺基，以产生芬氟拉明组成物。还提供了根据该方法制备的组成物和药物成分，包括芬氟拉明的药用可接受盐，并且总三氟甲基异构体重量小于0.2％。
• Crf Receptor Antagonists and Methods
  申请人：Luo Zhiyong

  公开号：US20070293511A1

  公开（公告）日：2007-12-20

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了具有治疗多种疾病的用途的CRF受体拮抗剂，包括治疗在恒温动物中表现为CRF过度分泌的疾病，如中风。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体、前药和药学上可接受的盐，其中R1、R2、R3、Y、Ar和Het的定义如本文所述。还揭示了含有CRF受体拮抗剂和药学上可接受的载体的组合物，以及使用它们的方法。
• SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE
  申请人：Ghosheh Omar

  公开号：US20090137653A1

  公开（公告）日：2009-05-28

  This invention is directed to substituted benzylamines which are useful as inhibitors of the CYP2A6 enzyme. Pharmaceutical compositions comprising the compounds and methods of using the compounds to treat nicotine dependence are also disclosed.

  本发明涉及替代苯甲胺类化合物，其可用作CYP2A6酶的抑制剂。还公开了包含该化合物的制药组合物以及使用该化合物治疗尼古丁依赖的方法。